DOCSLIB.ORG

Wo 2007/002780 A2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 4 January 2007 (04.01.2007) WO 2007/002780 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K9/00 (2006.01) A61K 47/34 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/18 (2006.01) A61L 12/14 (2006.01) AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, (21) International Application Number: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, PCT/US2006/025239 KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MZ, NA, (22) International Filing Date: 28 June 2006 (28.06.2006) NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 60/694,486 28 June 2005 (28.06.2005) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (71) Applicant (for all designated States except US): BAUSCH European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, & LOMB INCORPORATED [US/US]; One Bausch & FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, Lomb Place, Rochester, NY 14604-2701 (US). RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, (72) Inventors; and GN, GQ, GW, ML, MR, NE, SN, TD, TG). (75) Inventors/Applicants (for US only): LEVER, William, Jr. [US/US]; 14 Fenimore Drive, Pittsford, NY 14534 Published: (US). XIA, Erning [US/US]; 93 Chippenham Drive, Pen- — without international search report and to be republished field, NY 14526 (US). upon receipt of that report (74) Agents: LAVOIE, Paul, T. et al.; Bausch & Lomb In For two-letter codes and other abbreviations, refer to the "G uid corporated, One Bausch & Lomb Place, Rochester, NY ance Notes on Codes and Abbreviations" appearing at the beg in 14604-2701 (US). ning of each regular issue of the PCT Gazette. (54) Title: TOPICAL PRESERVATIVECOMPOSITIONS (57) Abstract: The use of one or more compositions of one or more preserving agents at a relatively high osmolality to disinfect contact lenses and preserve topical agents and ophthalmic lens compositions is described. Ophthalmic lens solutions containing one or more compositions of one or more preserving agents at a relatively high osmolality and methods of making and using the same are also described. TOPICAL PRESERVATIVECOMPOSITIONS Field of the Invention: The present invention is directed toward a composition with enhanced preservation. Background of the Invention: The most prevalent method of delivering an ocular pharmaceutical to the eye of a patient is to administer it topically in the form of drops, gels or ointments. To sell any topical ophthalmic pharmaceutical in the U.S for use over an extended period of time, the composition must prevent growth of microorganisms as defined in the preservative efficacy test. In the pharmaceutical industry, benzalkonium chloride is one of the most popular preservatives for topical ophthalmic formulations. However, benzalkonium chloride can destabilize the tear film and cause irritation. Benzalkonium chloride used with a medical device such as a contact lens can potentially bind to the medical device such as a contact lens. There is a need in the pharmaceutical industry for preservatives of topically applied compositions such as ophthalmic solutions, pharmaceuticals, artificial tears and comfort drops with a gentle preservative at as low possible volumes in the topically applied compositions. One class of solutions that are used of solution is a contact lens care solution, particularly contact lens care solutions that are not rinsed from the lens before a patient installs the lens in the eye. Multi-purpose lens care solutions both clean and disinfect the contact lens. Thus, higher levels of a disinfectant/preservative are required for multi-purpose lens care solutions. Particularly, to disinfect a lens, a disinfecting amount of a preservative/ disinfectant is needed. Potent, yet gentle, preservatives have been discovered that are sufficiently strong to disinfect a contact lens but will not cause considerable irritation when placed in the eye of the patient. U.S. Patent Number 4,758,595 discloses a contact lens disinfectant and preservative containing a biguanide or a water-soluble salt thereof in combination with a buffer, preferably a borate buffer, e.g., boric acid, sodium borate, potassium tetraborate, potassium metaborate or mixtures of the same. Alexidine is the trade name for 1,1'-hexamethylene-bis[5-(2- ethylhexyl)biguanide]. It is currently used as a disinfectant in a contact lens care solutions. Alexidine is known to be a gentle and potent antimicrobial agent in contact lenses. Poly(hexamethylene biguanide) or Alexidine are listed as one of several preservatives can be used to preserve topical ophthalmic formulations. No topical ophthalmic formulations have used poly(hexamethylene biguanide) or Alexidine as a preservative have been known to date. Nonetheless, there exists a need for a topical ophthalmic formulation that is gentle and effectively reduces the quantity of preservative that is required in solution. The present invention addresses these and other needs. Summary of the Invention The present invention relates to gentle preservative compositions useful for preserving topically applied agents such as ophthalmic solutions, pharmaceuticals, artificial tears and comfort drops against microbial contamination, and for preserving contact lens solutions. The subject preservative compositions are non-toxic, simple to use and do not cause ocular irritation. Additionally, preservative compositions of the present invention are suitable for use with all types of contact lenses, including rigid gas permeable contact lenses. Compositions formulated in accordance with the present invention include a relatively lower level, or a reduced volume-preserving amount, of one or more preservative agents in solution at a relatively higher osmolality for enhanced preservation. Such solutions including one or more compositions of the present invention at a higher osmolality are useful for preserving, soaking, rinsing, wetting and conditioning all types of contact lenses, including rigid gas permeable contact lenses. The higher osmolality of solutions of the present invention allows for the use of a relatively lowered level, or a reduced volume preserving amount, of one or more preservative agents while still achieving effective preservation of pharmaceuticals, ophthalmic solutions, medical devices and the like. Due to the presence of a lower level or a reduced volume- preserving amount of one or more preserving agents, patient comfort is increased and side effects are avoided. Hence, a more gentle preservative system is achieved. By reduced volume preserving amount it is meant an amount that is less than the minimum amount required to preserve a solution at an osmolality of 220 mOsmo/Kg. Accordingly, in one embodiment of the present invention the compositions and solutions have enhanced preserving activity useful in the manufacture of ophthalmic systems. Accordingly, in another embodiment of the present invention there is a method for using compositions with enhanced preserving activity in the preservation of contact lens care solutions. Accordingly, in one embodiment of the present invention the compositions and solutions have enhanced preservative activity useful in preserving ophthalmic systems from microbial contamination. Accordingly, in still another embodiment of the present invention there is a method of making compositions with enhanced preserving activity useful in ophthalmic systems. Accordingly, in an embodiment of the present invention there is a method of making compositions with enhanced preserving activity useful as preservative agents. In one embodiment, there is a composition comprising water and a reduced volume preserving amount of said one or more preserving agents selected from the group consisting of poly(hexamethylene biguanide), 1,1'- hexamethylene-bis[5-(2-ethylhexyl)biguanide] and combinations thereof. The composition has a high osmolality. In another embodiment, the composition further comprises water and a preserving amount of said one or more preserving agents selected from the group consisting of poly(hexamethylene biguanide), 1,1'-hexamethylene-bis[5- (2-ethylhexyl)biguanide] and combinations thereof. The composition further comprises a pharmaceutical agent. Optionally, the composition has a high osmolality. These and other objectives and advantages of the present invention, some of which are specifically described and others that are not, will become apparent from the detailed description and claims that follow. Detailed Description of the Invention Compositions of the present invention include one or more preserving agents. Suitable preserving agents for use in the present invention include for example but are not limited to 1,1'-hexamethylene-bis[5~(p- chlorophenyl)biguanide] (Chlorhexidine) or water soluble salts thereof, 1,1'- hexamethylene-bis[5-(2-ethylhexyl)biguanide] (Alexidine) or water soluble salts Thereof, poly(hexamethylene biguanide)
Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • Evaluation of Vaginal Antifungal Formulations in Vivo R. J. MCRIPLEY P

    Evaluation of Vaginal Antifungal Formulations in Vivo R. J. MCRIPLEY P

    Postgrad Med J: first published as 10.1136/pgmj.55.647.648 on 1 September 1979. Downloaded from Postgraduate Medical Journal (September 1979) 55, 648-652 Evaluation of vaginal antifungal formulations in vivo R. J. MCRIPLEY P. J. ERHARD Ph.D. B.S. R. A. SCHWIND R. R. WHITNEY B.S. B.A. The Squibb Institute for Medical Research, Princeton, New Jersey, U.S.A. Summary employed to establish the experimental infection. Relatively simple and rapid procedures have been Inocula for infection were prepared by harvesting developed for evaluating the local efficacy of vaginal the growth from Sabouraud's dextrose agar slants antifungal agents in vivo in a vaginal candidiasis model of C. albicans obtained after 24-48 hr incubation at in ovariectomized rats. The results of this investigation 37°C and making suspensions containing 10s colony- indicate that the model and methods described are forming units (CFU)/ml. quite suitable for screening potential antifungal sub- Protected by copyright. stances and for assessing the chemotherapeutic Establishment of the experimental infection effectiveness ofnew antifungal agents and formulations Rats were pretreated with 0.5 mg of progesterone before carrying out clinical studies. and 0.5 mg of oestradiol valerate administered sub- cutaneously to induce oestrus. Confirmation of Introduction oestrus was made by microscopic examination of Vaginal candidiasis is a common and chronic ailment vaginal smears. Beginning 2 days after hormonal in women of child-bearing age. The incidence of this treatment, rats were inoculated intravaginally on 2 vaginal infection has increased considerably in successive days with 107 CFU of C. albicans con- recent years with the more frequent use of anti- tained in a 0.1 ml inoculum.
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0019025A1 Gavin (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2004/0019025A1 Gavin (43) Pub

    US 20040019025A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0019025A1 Gavin (43) Pub. Date: Jan. 29, 2004 (54) MEDICAL COMPOSITIONS COMPRISING (30) Foreign Application Priority Data (R,R)-FORMOTEROLAND ROFLEPONIDE Apr. 18, 2000 (GB).......................................... OOO96O73 (76) Inventor: Brian Charles Gavin, Rathfarnfam (IE) Publication Classification Correspondence Address: DAVIDJ LEVY, CORPORATE (51) Int. Cl." ............................ A61L 9/04; A61K 31/58; INTELLECTUAL PROPERTY A61K 31/4745 GLAXOSMITHKLINE (52) U.S. Cl. ............................. 514/171; 424/45; 514/291 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398 (US) (57) ABSTRACT (21) Appl. No.: 10/257,702 The present invention is concerned with pharmaceutical formulations comprising a combination of (R,R)-formoterol (22) PCT Filed: Apr. 11, 2001 and rofileponide and the use of Such formulations in medi cine, particularly in the prophylaxis and treatment of respi (86) PCT No.: PCT/GB01/01629 ratory diseases. US 2004/0019025 A1 Jan. 29, 2004 MEDICAL COMPOSITIONS COMPRISING 0010 AS would be appreciated by the skilled person, (R,R)-FORMOTEROLAND ROFLEPONIDE rofileponide contains Several asymmetric centres. The 0001. The present invention is concerned with combina present invention includes each isomer of rofileponide, par tions of (R,R)-formoterol and rofleponide, particularly com ticularly the (22R) and (22S) isomers, either in substantially positions containing a combination of (R,R)-formoterol and pure form or admixed in any proportions. The isomers of rofileponide and the use of Such compositions in medicine, rofileponide have been described previously in WO particularly in the prophylaxis and treatment of respiratory 92/13872. diseases. 0011. By the term “physiologically functional derivative” 0002 Formoterol, i.e.
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al

    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
  • Ehealth DSI [Ehdsi V2.2.1] European Commission

    Ehealth DSI [Ehdsi V2.2.1] European Commission

    MTC eHealth DSI [eHDSI v2.2.1] European Commission - Master Translation/Transcoding Catalogue Responsible : eHDSI Solution Provider PublishDate : Thu Jun 01 17:03:48 CEST 2017 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73